NASDAQ:CNMD - CONMED Stock Price, News & Analysis

$101.61
-0.42 (-0.41 %)
(As of 09/19/2019 03:08 PM ET)
Today's Range
$100.85
Now: $101.61
$103.18
50-Day Range
$87.59
MA: $97.30
$102.72
52-Week Range
$56.90
Now: $101.61
$103.90
Volume82,612 shs
Average Volume182,000 shs
Market Capitalization$2.87 billion
P/E Ratio46.61
Dividend Yield0.79%
Beta0.54
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:CNMD
CUSIP20741010
Phone315-797-8375

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$859.63 million
Cash Flow$4.4275 per share
Book Value$23.54 per share

Profitability

Net Income$40.85 million

Miscellaneous

Employees3,100
Market Cap$2.87 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.


CONMED (NASDAQ:CNMD) Frequently Asked Questions

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED announced a quarterly dividend on Friday, August 2nd. Investors of record on Friday, September 13th will be paid a dividend of $0.20 per share on Monday, October 7th. This represents a $0.80 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend is Thursday, September 12th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) issued its earnings results on Wednesday, July, 31st. The medical technology company reported $0.56 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.53 by $0.03. The medical technology company earned $238.26 million during the quarter, compared to analyst estimates of $233.06 million. CONMED had a net margin of 3.13% and a return on equity of 9.95%. The business's quarterly revenue was up 12.0% on a year-over-year basis. During the same period last year, the firm posted $0.46 earnings per share. View CONMED's Earnings History.

When is CONMED's next earnings date?

CONMED is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED updated its FY19 earnings guidance on Wednesday, July, 31st. The company provided earnings per share (EPS) guidance of $2.52-2.57 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.49. The company issued revenue guidance of ~$951-958 million, compared to the consensus revenue estimate of $945.43 million.

What price target have analysts set for CNMD?

4 equities research analysts have issued 1-year target prices for CONMED's stock. Their forecasts range from $94.00 to $110.00. On average, they expect CONMED's stock price to reach $102.00 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Price Targets for CONMED.

What is the consensus analysts' recommendation for CONMED?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CONMED.

What are Wall Street analysts saying about CONMED stock?

Here are some recent quotes from research analysts about CONMED stock:
  • 1. According to Zacks Investment Research, "CONMED exited the second quarter on a solid note, with both earnings and revenues beating estimates. CONMED outperformed the industry in a year’s time. Its core units — Orthopedic Surgery and General Surgery — continue to bolster the top line. Solid international sales growth in recent times is a positive. Management is also confident of the company’s broad product portfolio. It anticipates the buyout of Buffalo Filter (completed in early 2019) to bolster CONMED’s General Surgery portfolio. Raised 2019 guidance buoys optimism in the stock. The company operates in a highly competitive environment, especially with respect to the General Surgery business. The company’s high long-term debt is a concern." (8/2/2019)
  • 2. Needham & Company LLC analysts commented, "CNMD’s 4Q18 revenue beat consensus while its EPS was in line with consensus. Management provided 2019 revenue and EPS guidance that were both above consensus. Revenue growth improved to 10.8% CC (or ~9.3% CC after adjusting for an extra selling day) in 4Q18 from 8.1% CC in 3Q18 despite a more difficult comp. CNMD’s revenue grew 8.4% in 2018, which is ~400 bps above the mid-point of its original 4-5% guidance. We believe that the 2019 revenue guidance is similarly conservative and note that management indicated that they intend to allow any revenue upside to fall through to the bottom line rather than reinvesting this as in 2018. Given this, we reiterate our Buy rating." (1/23/2019)

Has CONMED been receiving favorable news coverage?

Media coverage about CNMD stock has trended negative on Thursday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CONMED earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for CONMED.

Who are some of CONMED's key competitors?

What other stocks do shareholders of CONMED own?

Who are CONMED's key executives?

CONMED's management team includes the folowing people:
  • Mr. Curt R. Hartman, CEO, Pres & Director (Age 55)
  • Mr. Todd W. Garner, Exec. VP & CFO (Age 50)
  • Mr. Patrick J. Beyer, Pres of CONMED International (Age 53)
  • Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 44)
  • Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 44)

Who are CONMED's major shareholders?

CONMED's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.45%), BlackRock Inc. (14.45%), Vanguard Group Inc. (10.14%), Point72 Asset Management L.P. (2.62%), Northern Trust Corp (2.17%) and Fisher Asset Management LLC (1.80%). Company insiders that own CONMED stock include Charles Farkas, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Johonna Marie Pelletier, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED.

Which major investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of New York Mellon Corp, BlackRock Inc., BlackRock Inc., Man Group plc, Invesco Ltd., Bank of America Corp DE and Victory Capital Management Inc.. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Dirk Kuyper, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED.

Which major investors are buying CONMED stock?

CNMD stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Morgan Stanley, Vanguard Group Inc., Landscape Capital Management L.L.C., Balyasny Asset Management LLC, Wells Fargo & Company MN, Eagle Asset Management Inc. and Bahl & Gaynor Inc.. Company insiders that have bought CONMED stock in the last two years include Charles Farkas and Heather L Cohen. View Insider Buying and Selling for CONMED.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $101.47.

How big of a company is CONMED?

CONMED has a market capitalization of $2.87 billion and generates $859.63 million in revenue each year. The medical technology company earns $40.85 million in net income (profit) each year or $2.18 on an earnings per share basis. CONMED employs 3,100 workers across the globe.View Additional Information About CONMED.

What is CONMED's official website?

The official website for CONMED is http://www.conmed.com/.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.


MarketBeat Community Rating for CONMED (NASDAQ CNMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  360 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  651
MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Featured Article: Resistance Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel